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clinical electrophysiology has seen so many major advance-
ents within the past year that we have decided to limit our
eview to four areas: catheter ablation of atrial fibrillation
AF), advances in drug therapy, genetics, and device ther-
py. Even with these limitations, it is not possible to cite all
he worthwhile publications, and for this we offer our
incere apologies.
This paper is directed primarily to the clinical cardiologist
n an effort to keep our brethren informed with regard to
ajor advances in the understanding and treatment of
ardiac rhythm disorders.
RUG THERAPY FOR CARDIAC ARRHYTHMIAS
he search for newer, more effective antiarrhythmic agents
ontinues. There is special interest in drugs that target ion
hannels found predominantly in the atrium in hopes that
his will provide treatment of AF without the risk of
orsades. Studies examined the effects of blockers that target
kach (which may be important in the genesis of vagotonic
F) (1) or blockers of the Kv 1.5 or Kv 4.3 channels (2).
he aim is to find atrial selective K channel blockers and,
hus, obviate the risk for serious ventricular arrhythmias.
A concise review of current usage of drugs for both
upraventricular as well as ventricular arrhythmias was
uthored by Singh et al. (3). A drug approach to the
anagement of patients with ventricular arrhythmias due to
rugada syndrome was presented by Belhassen et al. (4).
hey felt that chronic oral quinidine therapy proved effec-
ive in the prevention of inducible ventricular fibrillation (in
he laboratory) as well as in the prevention of spontaneous
entricular arrhythmias. Of note, the authors used a very
emanding invasive electrophysiologic testing protocol, and
6% of patients could not tolerate long-term quinidine
herapy. If confirmed, this therapy may prove to be an
lternative to automatic implantable-cardioverter defibrilla-
ors (AICD) placement, especially in poorer countries
here AICD therapy is not an option.
This past year showed the introduction of several new
rugs that are still under investigation. Tedisimal is a new
lass III drug that blocks multiple K channels including
to, Ikach, IKur, IKs, and IKr. It is felt to be more potent in
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hannels. Hohnloser et al. (5) described a multicenter
ouble-blind, randomized placebo-control study sequential
scending-dose trial of intravenous tedisimal in 201 patients
ith AF or atrial flutter. They found a conversion to sinus
ate in 41% in those receiving 0.4 mg/kg and 51% in the 0.6
g/kg group but only 7% in the placebo group. There was
ne episode of monomorphic ventricular tachycardia and
ne of torsades, both in the 0.6 mg/kg group. This drug
ppears to be of comparable or greater efficacy compared to
butilide, but still carries the risk for ventricular arrhythmias.
Another newer investigational drug is a new amiodarone
nalogue (dronedarone) (6). Dronedarone is a noniodinated
miodarone derivative. It has widespread blocking activity
or Na, K, and Ca channels. In the Dronedarone
trial Fibrillation Study After Electrical Cardioversion
DAFNE), this drug appeared to be safe and effective in
revention of AF relapse. A drug trial using this agent in
atients with moderate-to-severe congestive heart failure
HF) was prematurely terminated because of increased risk
f death in the treated group.
There continues to be interest in the development of
rugs or drug combinations for acute chemical conversion of
F or atrial flutter. Hongo et al. (7) demonstrated the
fficacy and safety of combined agents (flecainide or
ropafenone) with ibutilide in acute conversion of AF.
imilarly, Chiladakis et al. (8) showed that the use of
butilide after oral propafenone proved safe and effective for
F conversion.
There has been great recent interest in the effects of
ardiac nonarrhythmic drugs in the prevention of AF.
everal laboratory studies have established the rationale for
se of angiotensin-converting enzyme or angiotensin recep-
or blockers in prevention or possible treatment of patients
ith AF. Sakabe et al. (9) used an atrial-pacing-induced AF
odel in canines. They showed that enalapril prevented
brosis and overexpression of connexin 43 in this model and
uppressed atrial-pacing-induced AF. In addition, Li et al.
10) showed that losartan was more effective than diltiazem
n preserving rate adaptation after rapid atrial pacing in
abbits, hence preventing the atrial electrical remodeling
hat contributes to AF maintenance. Several confirmatory
linical studies are now available. L’Allier et al. (11) re-
orted a retrospective longitudinal cohort study of patients
ith hypertension treated with either an angiotensin-
onverting enzyme inhibitor or calcium channel blocker.
hey found that a reduced incidence of AF in the group
t
Z
c
t
u
b
G
I
e
b
i
i
s
fi
d
t
f
o
m
(
s
T
t
b
m
c
m
a
m
n
b
b
t
m
d
(
m
n
g
p
t
w
g
v
e
p
t
d
s
K
o
g
p
r
L
L
t
t
p
w
c
w
o
p
p
D
A
z
e
p
t
a
C
i
o
i
r
H
a
1
t
a
d
v
5
d
f
c
w

s
p
r
T
f
c
b
a
L
d
p
d
a
o
791JACC Vol. 45, No. 5, 2005 Scheinman and Keung
March 1, 2005:790–5 Year in Clinical Electrophysiologyreated with the angiotensin-converting enzyme inhibitor.
aman et al. (12) found that long-term angiotensin-
onverting enzyme therapy facilitated electrical defibrilla-
ion in patients with persistent AF. Prospective studies
sing angiotensin-converting enzyme, angiotensin receptor
lockers, and/or statins are clearly required.
ENETIC SYNDROMES
mportant strides occurred over the past year in further
lucidation of the short QT syndrome. This syndrome has
een clinically categorized as consisting of a short QT
nterval (300 ms), tall peaked T waves, and a high
ncidence of sudden death (13). Invasive studies show a
hort refractory period and easily inducible ventricular
brillation. Brugada et al. (14) were the first to describe two
ifferent missense mutations resulting in abnormalities in
he S5-P loop region of the IKr channel (KCNH2). They
ound dramatic enhancement of the IKr current due to loss
f rectification of the IKr channel. In addition, this abnor-
al channel was not responsive to IKr blockers. Gaita et al.
15) tested six affected individuals with the short QT
yndrome with flecainide, sotalol, ibutilide, and quinidine.
hey found that only quinidine prolonged and normalized
he QT interval. It was felt that quinidine, because of its
road spectrum block of outward K currents, would be a
ore effective drug therapy than the more selective IKr
hannel blockers. Bellocq et al. (16) found a 70-year-old
an who presented with idiopathic ventricular fibrillation
nd was found to have the short QT syndrome due to a
utation in the KCNQ1 gene that encodes the IKs chan-
el. A number of other candidate K or Ca mutants may
e involved with this very interesting new syndrome.
Additionally, new potentially important findings have
een described for patients with the long QT syndrome. In
hese patients the syndrome has usually been attributed to
utations in coding regions of the gene. Zhang et al. (17)
escribed a novel intronic mutation that alters the KCNH2
IKr channel) gene. They conclude that intronic mutations
ay be responsible for the syndrome in families with
egative screening for the usual genes found in the long QT
enes. This may account for some of the 30% to 50% of
atients with long QT syndrome who have negative muta-
ional screens. Other interesting reports involve patients
ith the long QT syndrome due to loss of function of the
ene encoding IK1 channel (KCNJ2). This gene has pre-
iously been found to cause Andersen’s syndrome. Fodstad
t al. (18) showed two novel mutations in this gene
roducing the long QT syndrome without any other fea-
ures of Andersen’s syndrome. Westenskow et al. (19)
escribed compound mutations in 20 of 252 long QT
yndrome patients involving KVLQT1, HERG, KCNE1,
CNE2, and SCN5A genes. The compound mutation
ften resulted in a severe phenotypic pattern.
There were several manuscripts that provided furtherenotype-phenotype relationships that potentially impact aatient care. Priori et al. (20) showed that there was a higher
ecurrence of cardiac events in patients with LQT2 and
QT3 treated with beta-blockers compared to those with
QT1. These data support prior observations on the rela-
ive resistance of LQT2 and LQT3 patients to beta-blocker
herapy and raises the issue of use of a defibrillator for these
atients. In addition, Shimizu et al. (21) found that patients
ith LQT1 due to mutations in the transmembrane domain
arried a higher risk for cardiac events compared to those
ith a C-terminal mutation. The risk for cardiac events
ccurred at a younger age, and baseline and exercise QT
arameters (i.e., QTc, Q-T peak, or QT end) were more
ronounced for those with transmembrane mutations.
EVICE THERAPY
number of studies have shown that cardiac resynchroni-
ation therapy (CRT) resulted in improved symptoms and
xercise tolerance, as well as in enhanced left ventricular
erformance, and reduction in hospitalization for HF pa-
ients. These studies have not been adequately powered to
ssess the effects of CRT on mortality (22–25). The
omparison of Medical Therapy, Pacing and Defibrillation
n Heart Failure Trial (COMPANION) asked the question
f whether resynchronization pacing with or without an
mplantable cardioverter-defibrillator (ICD) reduced the
isk of death and hospitalization in patients with New York
eart Association functional class III to IV congestive HF
nd a wide QRS complex (26). In this multicenter trial,
,520 patients were randomized to receive optimal medical
herapy (308 patients), a CRT pacemaker (617 patients), or
CRT  ICD (595 patients). There were no significant
ifferences in left ventricular ejection fraction (LVEF), 20%
s. 22%; incidence of ischemic heart disease, 54% versus
9%; or QRS duration between the CRT versus CRT-
efibrillator groups. The primary end point included death
rom and/or hospitalization for any cause. Death from any
ause alone was a secondary end point. When compared
ith the medical therapy group, both the CRT (hazard ratio
0.81) and the CRT  ICD (hazard ratio  0.80) groups
ignificantly decreased the risk of the primary composite end
oint by 20%. Only the CRT  ICD group significantly
educed death from any cause (36%) (hazard ratio  0.64).
he results strongly suggest that the optimal device therapy
or patients with severe HF and widened QRS duration
onsists of a CRT  ICD because of the added survival
enefit. This study was not powered to determine whether
n ICD without CRT would achieve a survival benefit.
The mortality benefit of ICD in patients with impaired
VEF due to ischemic cardiomyopathy has been well
ocumented. The value of primary prevention of death in
atients with nonischemic dilated cardiomyopathy was ad-
ressed by the Defibrillators in Non-ischemic Cardiomyop-
thy Treatment Evaluation trial (DEFINITE) (27). A total
f 458 patients with nonischemic dilated cardiomyopathy
nd reduced LVEF (mean value  0.21) were randomized
i
m
p
e
a
i
m
t
T
o
r
I
(
C
t
c
H
a
w
h
W
t
(

g
D
o
o
H
1
a
r
1
s
s
p
t
M
f
a
o
b
r
h
c
t
b
w
i
o
d
p
t
p
e
r
c
p
c
i
r
n
(
p
t
a
p
m
i
a
w
d
a
c
o
a
A
c
a
t
s
r
t
d
m
a
a
L
A
t
w
3
o
3
2
8
o
o
t
r
d
a
f
s
s
a
792 Scheinman and Keung JACC Vol. 45, No. 5, 2005
Year in Clinical Electrophysiology March 1, 2005:790–5n equal numbers to standard medical therapy and standard
edical therapy plus a single-chamber ICD. Eight-five
ercent of the patients received an angiotensin-converting
nzyme inhibitor and beta-blockers, while 5% were taking
miodarone. The ICD group showed a significantly reduced
ncidence of sudden death (80%) (hazard ratio  0.20), and
ortality rates at two years were 14.1% in the standard
herapy group and 7.9% in the ICD group (not significant).
hese results were attributed to the relatively small size
f this trial and the lower-than-expected annual mortality
ate in the standard therapy group. A recently completed
CD trial, Sudden Cardiac Death in Heart Failure trial
SCD-HeFT), was presented at the American College of
ardiology Annual Scientific Session in 2004 (28). This
rial examined whether amiodarone or ICD reduced all-
ause mortality compared to placebo in patients with either
F due to ischemic or nonischemic dilated cardiomyopathy
nd reduced LVEF (0.35 or less). A total of 2,521 patients
ere enrolled, and approximately equal number of patients
ad ischemic (52%) or nonischemic cardiomyopathy (48%).
hen compared to placebo treatment, ICD reduced mor-
ality by 23%. The reduction was observed in both ischemic
hazard ratio  0.79) and nonischemic groups (hazard ratio
0.73), regardless of QRS duration. The amiodarone
roup did not show improved survival. The results of the
EFINITE and SCD-HeFT studies support implantation
f an ICD in patients with nonischemic dilated cardiomy-
pathy with reduced LVEF and moderate HF (New York
eart Association functional class II and III).
Since the introduction of dual-chamber pacemaker in the
980s, DDD pacing mode had been promoted to preserve
trioventricular synchrony despite absence of large-scale,
andomized prospective trials demonstrating benefits. In
997, Andersen et al. (29) reported that in 225 patients with
inus node dysfunction, atrial pacing (AAI) resulted in
ignificantly lower cardiovascular death than ventricular
acing (VVI) (29). Recently, two large randomized trials,
he Canadian Trial Physiological Pacing (CTOPP) and the
ode Selection Trial in Sinus Node Dysfunction (MOST)
ailed to demonstrate a difference in survival between VVI
nd dual-chamber pacing (30,31). In 2000, after three years
f follow-up, the CTOPP study reported no significant
enefits of physiological (DDD or AAI) pacing over VVI in
educing cardiovascular death or stroke, overall mortality, or
ospitalization for HF. There was a moderate and statisti-
ally significant increase in the incidences of AF for those
reated with VVI. To ascertain the presence of delayed
eneficial effects of physiologic pacing mode, the follow-up
as extended for another three years. In 2004, the CTOPP
nvestigators reexamined the results after a mean follow-up
f 6.4 years (32). There were no differences in cardiovascular
eath or stroke, or total mortality between patients im-
lanted with ventricular versus physiologic pacemakers, and
he incidence of AF remained higher in patients with VVI
acing. However, there was no difference in the composite
nd point of cardiovascular death or stroke. This large iandomized trial with long-term follow-up failed to provide
lear support for dual-chamber pacemakers that are general
referred by implanting physicians for bradytherapy in this
ountry.
Curative catheter ablation of AF continues to excite the
nterventionalists. It is now recognized that sustained AF
eflects interaction between triggers (largely in the pulmo-
ary veins [PV]) (33) and substrate (largely the left atrium)
34). This has led to the introduction of techniques for
ulmonary vein isolation (PVI) (35), to address the issue of
riggers from these sources, and circumferential left atrial
blation (LACA) (36), which involves wide lesions encom-
assing the PVs together with additional lesions that are
eant to join the superior veins and a so-called mitral
sthmus lesion that joins the left inferior PV to the mitral
nnulus.
An entirely new approach solely directed at the substrate
as introduced by Nademanee et al. (37). This group
irected ablative lesions to areas showing complex fraction-
ted electrograms in 110 patients with paroxysmal or
hronic AF. They found that these electrograms tended to
ccur over the atrial septum but were also found in PVs left
trial roof, posterior mitral annulus, and coronary sinus os.
blation of these targets resulted in a 95% spontaneous
onversion to sinus rhythm, and 91% of patients were
rrhythmia free after one year. Seven patients required drug
herapy and 18 required a second ablation. The authors
uggest that the complex electrograms represent continuous
e-entry of fibrillatory waves or overlap of wavelets entering
his area. Regardless of the mechanism, they have nicely
emonstrated that a totally new approach to substrate
odification may play an important therapeutic role.
In an important follow-up study, Oral et al. (38) reported
randomized study using a variant of the left atrial catheter
blation (LACA) technique. They performed the typical
ACA technique (as previously described) in 100 patients.
fter completion of the procedure, there was spontaneous
ermination of AF in 40 patients. The remaining patients
ere randomly assigned to no further ablation (group 2 
0 patients) or to further ablation of fractioned electrograms
ver the left atrial septum, roof, or anterior walls (group 3
0 patients). Of interest AF was rendered noninducible in
7 of 30 patients in group 3. After a six-month follow-up,
6% of the group 3 patients and 67% of group 2 were free
f AF without drug therapy. This study complements the
bservations of Nademanee et al. (5) with respect to
echniques directed at substrate alteration.
Haïssaguerre et al. (39) showed that sequential PVI
esulted in an increase in AF cycle length parri passu with
elivery of peripulmonary venous lesions as well as with
dditional linear left atrial lesions. They noted a decrease in
ragmentation of the electrograms before conversion to
inus or atrial flutter. This study tends to support the prior
tudies relating to substrate modifications, although the
uthors attributed this finding to “extinguishing perpetuat-
ng activations” from the PVs.
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March 1, 2005:790–5 Year in Clinical ElectrophysiologyThe vagal effects on initiation and perpetuation of AF are
ell recognized (40). Pappone et al. (41) presented new
ndings relating to purposeful denervation of vagal efferents
o the left atrium. They found that vagal responses were
requently elicited in the course of LACA, manifest by sinus
radycardia, atrioventricular block, and hypotension. They
ound that vagal reflexes could be elicited and abolished
with continued radiofrequency application) in about one-
hird of patients. They found persistent loss of vagal activity
s manifest by sinus tachycardia and/or abnormal heart rate
ariability. Freedom from recurrent AF after 12 months
anged from 99% in those without vagal reflexes, compared
ith 85% in those with intact vagal tone (p  0.0002). The
uthors concluded that parasympathetic attenuation during
V ablation confers added benefit to the LACA procedure.
hese studies will likely fuel a wide variety of studies to
valuate the role of autonomic influences for patients with
F treated by catheter ablation.
Another study that addressed the role of autonomic
nfluences for those undergoing AF ablation was reported by
ral et al. (42). They divided 188 consecutive AF patients
nto those with random (72%), adrenergic (16%), or vagally
ediated AF (12%). The patients underwent isolation of
hree or four PVs. At one year of follow-up, 69% of those
ith random, 83% of those with adrenergic, and 50% of
hose with vagotonic AF were free of recurrent AF without
ntiarrhythmic drugs. It would appear that PV isolation is
ess effective for those with vagotonic AF. A natural study
ould be to assess the effects of vagal denervation as
escribed by Pappone et al. (41) in patients with vagotonic
F.
A very important complication after AF ablation is the
evelopment of atrial flutter. Over the past year, a number
f studies have focused on the mechanism of this arrhyth-
ia. It is clear that rapid, organized left atrial rhythms may
ccur just after left atrial ablation. Many of these have no
ong-term clinical expression. However, some patients may
evelop clinically significant left atrial tachycardias. Ger-
tenfeld et al. (43) reported a 2.9% incidence (10 patients) of
ecurrent tachycardia after PVI. In 8 of the 10 patients, the
achycardia was shown to be focal, and in 6 it appeared to
rise from reconnected areas from previously ablated re-
ions. Other focal sites included the posterior left atrium
33) or superior septum (33). In their experience, recurrent
utter was uncommon and usually arose from (and was
uccessfully ablated) from reconnected PV ostial sites.
In contrast, Mesas et al. (44) described 13 patients with a
eft atrial tachycardia after a LACA. In their experience only
hree were focal, and the rest were macroreentry with either
ingle- or double-loop configurations. The reentrant circuits
nvolved the posterior left atrial wall, mitral isthmus, or gaps
n the previous ablation lines. It would appear that complex
acro–re-entrant tachycardia circuits are much more com-
on after LACA compared with PVI. Finally, Scharf et al.
45) also found both focal as well as macroreentrant rhythms
fter left atrial ablation.There are several important reports relative to complica-
ions of AF ablation. The most frightening were reports of
evelopment of atrioesophageal fistula after left atrial abla-
ion. Two patients developed endocarditis associated with
aseous and septic emboli, and documented atrioesophageal
stula were reported (46). Signs of endocarditis, hemate-
esis, or systemic emboli should bring this complication to
ind. This complication requires urgent surgery. Operators
re warned to avoid use of high-power energy application to
he posterior wall of the left atrium. Others have suggested
se of esophageal probes to monitor the temperature in the
sophagus during left atrial ablation. Another important
omplication after PVI is the development of PV stenosis. A
otentially important study from Australia (47) suggests
hat, although stenosis was initially found in 16% of
atients, PV stenosis was either unchanged (eight patients),
mproved, or fully resolved in five patients, and deteriorated
n one patient. They point out that absent PV stenosis after
he first procedure does not ensure that this complication
ould not occur with repeat ablation.
Lickfett et al. (48) studied the possible hazard of radiation
xposure during the often lengthy AF catheter procedure.
he projected lifetime risk of excess malignancy was 0.07%
or females and 0.1% for males. They felt that the relatively
mall amount of radiation exposure despite the length of the
rocedure was due to very-low-frame pulsed fluoroscopy.
he projected lifetime risk of fatal malignancy was similar
o that previously reported for other ablative procedures
i.e., atrioventricular nodal or atrioventricular reentrant
achycardia).
The Cleveland Clinic group found that the PVI proce-
ure was nearly as effective for those with impaired systolic
unction compared to those with normal function (49).
hey, moreover, found that PVI proved safe and effective
or all age groups with AF but did report a higher incidence
f thromboembolic complications in the elderly. They
ound a 3% incidence of stroke in those over 60 years of age,
ompared with none in those younger than 60 years of age
50). This important finding must be integrated into our
iscussions of AF ablation in older patients.
Cardiovascular surgeons continue to be very active in
evising new techniques and procedures for operative cure
f AF. This is largely performed in patients requiring
oncomitant cardiac surgery (51). The newer techniques
nvolve microwave application (52), and use of cryoablation
53,54), as well as endoscopic robotic-guided ablation pro-
edures (55).
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